恩諾沙星
Enrofloxacin
1-cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
別名: Baytril · Enrocare · Enrox · Xeden · Zobuxa · Bay-Vp-2674 · Enrofloxacine · Enrofloxacino · Enrofloxacinum
由 VetSheet 獸醫團隊審訂更新於 2026年4月5日本內容以實證獸醫文獻為本
劑量為合格獸醫專業人員的臨床參考。請務必對照最新仿單及個別病患確認。
各物種劑量
🌎 NA — North America🌍 EU — Europe
狗
| 適應症 | 劑量 | 途徑 | 頻次 | 療程 | 地區 |
|---|---|---|---|---|---|
| Susceptible infections | 5-20 mg/kg per day PO | PO | q24h or divided q12h | At least 2-3 days beyond cessation of clinical signs, max 30 days | 🌎 NA |
| Sepsis | 5-20 mg/kg IV | IV | q12h | — | 🌎 NA |
| Skin, urinary infections | 2.5-5 mg/kg PO | PO | q12h | 7-14 days | 🌎 NA |
| Deep pyodermas, complicated urinary infections | 5 mg/kg PO | PO | q24h | 7-14 days (up to 10-12 weeks for deep pyoderma) | 🌎 NA |
| Lower respiratory tract infections | 5-10 mg/kg PO | PO | q24h | 7-84 days | 🌎 NA |
| Prostate infections | 5 mg/kg PO | PO | q12h | 7-14 days | 🌎 NA |
| Histiocytic ulcerative colitis | 5 mg/kg PO | PO | q12h | 21-90 days | 🌎 NA |
| Histiocytic ulcerative colitis | 5-10 mg/kg PO | PO | q24h | At least 4-6 weeks | 🌎 NA |
| Hemotropic mycoplasmosis | 5 mg/kg PO, IM | PO, IM | q12h | 7-14 days | 🌎 NA |
| Systemic orthopedic infections | 5-11 mg/kg PO, IV, IM, SC | PO, IV, IM, SC | q12h | 10 days | 🌎 NA |
| Pseudomonas infections in soft tissues | 11-20 mg/kg PO, IM, SC | PO, IM, SC | q12h | 7 days minimum | 🌎 NA |
| Bacteremia, sepsis | 11 mg/kg PO, IV, IM, SC | PO, IV, IM, SC | q12h | As long as necessary | 🌎 NA |
| Susceptible infections | 5 mg/kg | SC | q24h | Not specified | 🌍 EU |
| Prostatitis or specific sites | 10 mg/kg | SC | q24h | Not specified | 🌍 EU |
- Susceptible infections: Pulse dosing regimens may be effective.
- Prostatitis or specific sites: Even higher doses may be necessary for certain isolates of Pseudomonas aeruginosa. Contact manufacturer to discuss.
貓
| 適應症 | 劑量 | 途徑 | 頻次 | 療程 | 地區 |
|---|---|---|---|---|---|
| Susceptible infections | 5 mg/kg per day PO | PO | q24h or divided q12h | At least 2-3 days beyond cessation of clinical signs, max 30 days | 🌎 NA |
| Hemoplasmosis | 5-10 mg/kg PO | PO | q24h | 14 days | 🌎 NA |
| Susceptible infections | 5 mg/kg | SC | q24h | Not specified | 🌍 EU |
| Susceptible infections | 2.5 mg/kg | PO | q12h | Not specified | 🌍 EU |
| Susceptible infections | 5 mg/kg | PO | q24h | Not specified | 🌍 EU |
- Susceptible infections: Do not exceed 5 mg/kg/day due to risk of blindness.
- Susceptible infections: Do not exceed 5 mg/kg/day due to risk of irreversible retinal blindness.
- Susceptible infections: Do not exceed 5 mg/kg/day total.
- Susceptible infections: Do not exceed 5 mg/kg/day total.
小型哺乳類
| 適應症 | 劑量 | 途徑 | 頻次 | 療程 | 地區 |
|---|---|---|---|---|---|
| Pasteurella upper respiratory infections in rabbits | 15-20 mg/kg PO | PO | q12h | Minimum 14 days to several months | 🌎 NA |
| Pasteurella in rabbits | 5 mg/kg PO, SC, IM or IV | PO, SC, IM, IV | q12h | 14 days | 🌎 NA |
| Susceptible infections in hedgehogs | 5-10 mg/kg PO or SC | PO, SC | q12h | — | 🌎 NA |
| Susceptible infections in chinchillas | 5-10 mg/kg PO, IM | PO, IM | q12h | — | 🌎 NA |
| Mycoplasmal pneumonia in mice and rats | 10 mg/kg PO | PO | q12h | — | 🌎 NA |
| Susceptible infections in Chinchillas, Gerbils, Guinea Pigs, Hamsters, Mice, Rats | 5-10 mg/kg PO or IM q12h or 5-20 mg/kg PO or SC q24h | PO, IM, SC | q12h or q24h | — | 🌎 NA |
| Susceptible infections in Chinchillas, Gerbils, Guinea Pigs, Hamsters, Mice, Rats (Drinking water) | 50-200 mg/liter | PO | Continuous | 14 days | 🌎 NA |
| Chronic respiratory disease in rats | 10-25 mg/kg PO | PO | q12h | — | 🌎 NA |
- Pasteurella upper respiratory infections in rabbits: First dose may be SC, do NOT give subsequent doses SC.
- Pasteurella in rabbits: If giving SC, dilute or skin may slough.
- Mycoplasmal pneumonia in mice and rats: Given with doxycycline.
- Susceptible infections in Chinchillas, Gerbils, Guinea Pigs, Hamsters, Mice, Rats: Do not use in young animals.
- Chronic respiratory disease in rats: If using theophylline concurrently, reduce theophylline dose by 30%.
雪貂
| 適應症 | 劑量 | 途徑 | 頻次 | 療程 | 地區 |
|---|---|---|---|---|---|
| Susceptible infections | 10-20 mg/kg PO, IM, SC | PO, IM, SC | q12h | — | 🌎 NA |
鳥
| 適應症 | 劑量 | 途徑 | 頻次 | 療程 | 地區 |
|---|---|---|---|---|---|
| Empirical treatment in stable, immunocompetent Psittacines | 20 mg/kg PO | PO | q24h | — | 🌎 NA |
| Debilitated immunocompetent Psittacines | 15-20 mg/kg SC in fluid pocket | SC | q24h | — | 🌎 NA |
| Debilitated, immunocompromised Psittacines | 15-20 mg/kg SC in fluid pocket | SC | q12h | — | 🌎 NA |
| Susceptible infections in Ratites | 1.5-2.5 mg/kg PO or SC | PO, SC | q12h | — | 🌎 NA |
| Susceptible infections in Ratites (Drinking water) | 10% solution, 10 mg/kg | PO | Daily | 3 days | 🌎 NA |
| Susceptible infections in Ratites (IM) | 5 mg/kg IM | IM | q12h | 2 days | 🌎 NA |
- Empirical treatment in stable, immunocompetent Psittacines: Given with amoxicillin/clavulanate.
- Susceptible infections in Ratites (IM): IM injections cause severe muscle necrosis.
爬蟲類
| 適應症 | 劑量 | 途徑 | 頻次 | 療程 | 地區 |
|---|---|---|---|---|---|
| Susceptible respiratory infections for most species | 5 mg/kg IM | IM | Every 5 days | 25 days | 🌎 NA |
| Chronic respiratory infections in tortoises | 15 mg/kg IM | IM | Every 72 hours | 5-7 treatments | 🌎 NA |
馬
| 適應症 | 劑量 | 途徑 | 頻次 | 療程 | 地區 |
|---|---|---|---|---|---|
| Susceptible infections | 5 mg/kg IV q24h; 5-7.5 mg/kg PO q24h | IV, PO | q24h | — | 🌎 NA |
| Susceptible respiratory infections | 7.5 mg/kg PO or IV | PO, IV | q24h | — | 🌎 NA |
| Susceptible infections (using compounded gel) | 7.5 mg/kg PO | PO | q24h | — | 🌎 NA |
- Susceptible infections: Use in horses is controversial. Only use in adults when other antibiotics are inappropriate.
- Susceptible infections (using compounded gel): Fast for 11-14 hours prior and 1-2 hours after dosing. Rinse mouth with water after dosing.
牛
| 適應症 | 劑量 | 途徑 | 頻次 | 療程 | 地區 |
|---|---|---|---|---|---|
| Bovine respiratory disease | 2.5-5 mg/kg SC once daily for 3-5 days or 7.5-12.5 mg/kg SC once | SC | q24h or single dose | 3-5 days or once | 🌎 NA |
- Bovine respiratory disease: Not for dairy cattle or veal calves. 28-day slaughter withdrawal. Extra-label use prohibited.
羊
| 適應症 | 劑量 | 途徑 | 頻次 | 療程 | 地區 |
|---|---|---|---|---|---|
| Susceptible infections in alpacas (Camelids) | 5 mg/kg SC or 10 mg/kg PO | SC, PO | q24h | — | 🌎 NA |
劑量為合格獸醫專業人員的臨床參考。請務必對照最新仿單及個別病患確認。
概覽
恩諾沙星 (Enrofloxacin) 是一種廣效、濃度依賴型的氟喹諾酮類抗生素，專為獸醫使用而開發。
- 抗菌譜：對多種革蘭氏陰性桿菌（如綠膿桿菌、大腸桿菌、克雷伯氏菌、沙門氏菌）及許多革蘭氏陽性球菌（如葡萄球菌，包括抗甲氧西林菌株）具有高度療效。
- 限制：對厭氧菌的活性較弱，對鏈球菌的療效不一。
- 臨床要點：具有高度脂溶性，能提供極佳的組織穿透力，包括前列腺、骨骼、腦脊髓液及細胞內（如巨噬細胞內）等難以到達的部位，對於深層及細胞內感染非常有效。
作用機轉
Enrofloxacin exerts its rapid bactericidal effect by targeting key bacterial enzymes involved in DNA replication and transcription:
- Inhibits DNA gyrase (Topoisomerase II) → prevents the negative supercoiling of bacterial DNA required for replication.
- Inhibits Topoisomerase IV → interferes with the separation of interlinked replicated DNA molecules.
Result: Disruption of DNA synthesis → double-strand DNA breaks → rapid bacterial cell death within 20-30 minutes of exposure.
Pharmacodynamic Pearl: Enrofloxacin exhibits a significant post-antibiotic effect (PAE) for both Gram-negative and Gram-positive bacteria, meaning bacterial growth continues to be suppressed even after drug concentrations fall below the Minimum Inhibitory Concentration (MIC).
安全性與警告
禁忌症
- Small and medium breed dogs 2 to 8 months of age (risk of cartilage damage)
- Large and giant breed dogs during their rapid-growth phase (may extend past 8 months)
- Patients hypersensitive to quinolones
- Foals (highly susceptible to arthropathic effects)
- Food-producing animals (extra-label use is strictly prohibited by the FDA)
- Dairy cattle or veal calves
- Growing dogs (<1 year of age; large-breed dogs <18 months of age)
- Cats <8 weeks of age
- Animals with known seizure disorders (relative contraindication)
不良反應
- Gastrointestinal distress (vomiting, anorexia, diarrhea)
- CNS stimulation (seizures, depression, lethargy, nervousness, ataxia)
- Cartilage abnormalities in young, growing animals
- Ocular toxicity/blindness in cats (at doses >5 mg/kg/day)
- Crystalluria (especially in dehydrated patients)
- Hypersensitivity reactions
- Elevated hepatic enzymes
- Tissue damage or pain at injection site (especially SC)
- Irreversible retinal blindness (cats)
- Cartilage abnormalities (growing dogs)
- Gastrointestinal upset (vomiting, diarrhea, anorexia)
- CNS toxicity / seizures (especially at high doses or with NSAIDs)
注意事項
Use with caution in patients with seizure disorders due to potential CNS stimulation.
Ensure patients remain well-hydrated to prevent crystalluria.
Patients with severe renal or hepatic impairment may require dosage adjustments to prevent drug accumulation.
Intravenous Administration Risks: Rapid or undiluted IV administration in dogs increases the risk of cardiac arrhythmias, hypotension, vomiting, and mast cell degranulation. Do not mix injectable enrofloxacin with any IV solution containing magnesium (e.g., Normosol-R, Plasmalyte) as micro-precipitants can lodge in the lungs, causing morbidity or mortality.
Feline Precautions: Doses exceeding 5 mg/kg/day in cats are associated with severe ocular toxicity, including irreversible retinal degeneration and blindness.
藥物交互作用
Cations bind to enrofloxacin and prevent its absorption; separate doses by at least 2 hours.
Synergism may occur, though unpredictable against some bacteria like Pseudomonas aeruginosa.
May exacerbate nephrotoxicity and reduce the metabolism of systemic cyclosporine.
Increases the AUC and elimination half-life of both enrofloxacin and flunixin in dogs.
Severe hypoglycemia is possible.
Decreased enrofloxacin absorption; separate doses by at least 2 hours.
Increased methotrexate levels possible, resulting in toxicity.
May antagonize the antimicrobial activity of fluoroquinolones; concomitant use is not recommended.
May alter phenytoin blood levels.
Blocks tubular secretion of ciprofloxacin (active metabolite), increasing its blood level and half-life.
Increased risk for cardiotoxicity.
May inhibit absorption of enrofloxacin; separate doses by at least 2 hours.
May increase theophylline blood levels (by about 30-50% in dogs).
Potential for increased warfarin effects.
Binds fluoroquinolones, preventing GI absorption
Inhibits absorption (separate dosing by at least 2 hours)
May reduce the clearance of fluoroquinolones
Decreases metabolism and increases nephrotoxicity of ciclosporin
Decreases metabolism and increases nephrotoxicity of tacrolimus
Potentiates CNS adverse effects (seizure risk)
May increase the action of anticoagulants
監測
- Clinical efficacy (resolution of infection)
- Adverse effects (GI upset, CNS signs)
- In cats: Monitor closely for mydriasis (dilated pupils) and/or retinal changes/vision loss
- Vision and pupillary light reflexes in cats
- Neurological status, especially in patients with a history of seizures
- Joint pain or lameness in young animals (if inadvertently administered)
藥物動力學
半衰期
吸收
Well absorbed after oral administration in most species. In dogs, oral bioavailability is ~80% (twice that of ciprofloxacin). Horses: 60-80%. Sheep: 65-75%. Peak levels (Cmax) occur within 1 hour of dosing. Food may delay the rate but not the extent of absorption.
分佈
Widely distributed throughout the body. Volume of distribution (Vd) in dogs is ~3-4 L/kg. Only ~27% bound to canine plasma proteins. Concentrates in macrophages, bile, kidney, liver, lungs, and reproductive system (prostate). Therapeutic levels attained in bone, synovial fluid, skin, muscle, aqueous humor, and pleural fluid. Low concentrations in CSF (6-10% of serum levels).
代謝
Metabolized to various metabolites. Approximately 10-40% of circulating enrofloxacin is metabolized to the active compound ciprofloxacin in most species (dogs, cats, adult horses, cattle, turtles, snakes). Foals, pigs, and some lizards do not convert much enrofloxacin to ciprofloxacin.
排除
Eliminated via both renal (tubular secretion and glomerular filtration) and non-renal (feces/hepatic) mechanisms. Approximately 15-50% is eliminated unchanged in the urine.
過量
Acute overdoses in dogs typically result in gastrointestinal signs (anorexia, vomiting). Dogs receiving 10X the labeled dose for 14 days developed only vomiting and anorexia. However, extreme overdoses (25X the labeled rate for 11 days) resulted in death.
In cats, overdoses can be severe and irreversible. Doses of 20 mg/kg or more can cause retinopathy, blindness, and seizures.
Common signs of toxicity reported to poison control include vomiting, lethargy, seizures, anorexia, depression, and diarrhea in dogs; and seizures and recumbency in cats.
可用產品
劑型
- Tablets (film-coated)
- Oral taste tablets
- Injectable solution (2.27% for small animals, 10% for large animals)
- Compounded oral suspension or gel
- Injectable: 25 mg/ml, 50 mg/ml
- Oral tablets: 15 mg, 50 mg, 100 mg, 150 mg, 200 mg, 250 mg
- Oral solution: 25 mg/ml
獸醫用
- Enrofloxacin Tablets (Film-Coated) & Oral Taste Tablets: 22.7 mg, 68 mg, 136 mg (Baytril)
- Enrofloxacin Injection: 22.7 mg/mL (2.27%) in 20 mL vials (Baytril)
- Enrofloxacin Injection: 100 mg/mL (10%) in 100 mL and 250 mL bottles (Baytril 100)
- Enrocare
- Enrotron
- Enroxil
- Fenoflox
- Floxabactin
- Powerflox
- Quinoflox
- Xeden
- Zobuxa
人用標示
- None
各地核准狀態
POM-V. Subject to strict antimicrobial stewardship guidelines.
POM-V
暫無法規資料: 🇺🇸 US · 🇭🇰 HK · 🇹🇼 TW · 🇯🇵 JP · 🇰🇷 KR · 🇦🇺 AU
儲存與穩定性
Tablets should be stored in tight containers at temperatures less than 30°C and protected from strong UV light. The 2.27% injection should be protected from light and not frozen. The 10% cattle injection should be protected from sunlight, not refrigerated or frozen, and stored below 40°C (104°F). If exposed to cold, precipitation may occur; warm and shake to redissolve.
飼主須知
貓咪主人重要須知：絕對不可超過獸醫師指示的劑量。在貓咪身上使用過高劑量可能會導致永久性失明。如果您發現貓咪的瞳孔異常放大或似乎有視力障礙，請立即停藥並聯絡您的獸醫師。
- 給藥方式：最好在空腹時給予此藥物。但如果服藥後導致您的寵物嘔吐或感到不適，可以改為與少量食物一起餵食。
- 藥錠處理：請勿壓碎膜衣錠。藥物內部味道非常苦，壓碎後會導致寵物拒食或過度流口水。
- 水分補充：在服藥期間，請確保您的寵物隨時有充足的新鮮飲水，以預防尿液中出現結晶。
- 幼年動物：此藥物通常不建議用於生長期的幼犬或幼貓，因為它可能會干擾正常的關節和軟骨發育。
VetSheet 藥物參考供合格獸醫專業人員作臨床決策輔助之用，不能取代專業判斷或廠商最新仿單。